Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $88.22.
A number of research firms have commented on GILD. HSBC began coverage on shares of Gilead Sciences in a research report on Wednesday, September 6th. They set a “reduce” rating and a $71.00 price target on the stock. Morgan Stanley boosted their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock an “equal weight” rating in a report on Friday, August 4th. Leerink Partnrs reiterated a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. UBS Group dropped their target price on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Gilead Sciences in a report on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price on the stock.
Insider Activity at Gilead Sciences
Institutional Trading of Gilead Sciences
Large investors have recently added to or reduced their stakes in the business. WealthPlan Investment Management LLC grew its position in Gilead Sciences by 121.2% in the second quarter. WealthPlan Investment Management LLC now owns 2,070 shares of the biopharmaceutical company’s stock worth $971,000 after acquiring an additional 1,134 shares in the last quarter. American Trust bought a new stake in Gilead Sciences in the first quarter worth approximately $289,000. Venturi Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter worth $36,000. Savant Capital LLC lifted its stake in shares of Gilead Sciences by 1.3% in the second quarter. Savant Capital LLC now owns 26,776 shares of the biopharmaceutical company’s stock worth $2,064,000 after buying an additional 356 shares during the last quarter. Finally, First National Trust Co lifted its stake in shares of Gilead Sciences by 10.2% in the first quarter. First National Trust Co now owns 2,774 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 257 shares during the last quarter. 82.33% of the stock is owned by institutional investors.
Gilead Sciences Trading Up 1.2 %
Gilead Sciences stock opened at $75.45 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.34 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $76.82 and a two-hundred day moving average price of $77.30. The firm has a market capitalization of $94.01 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.00 and a beta of 0.32. Gilead Sciences has a 52-week low of $72.87 and a 52-week high of $89.74.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The company had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. During the same period in the previous year, the firm earned $1.90 EPS. Gilead Sciences’s revenue was up .1% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences will post 6.76 earnings per share for the current year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 64.38%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
- Five stocks we like better than Gilead Sciences
- With Risk Tolerance, One Size Does Not Fit All
- 3 large caps with red hot RSIs with upside
- What is the NASDAQ Stock Exchange?
- Johnson Controls International: Nothing but upside for investors
- How is Compound Interest Calculated?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.